Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for the treatment of type 2 diabetes. It works by stimulating insulin secretion and inhibiting glucagon secretion, leading to improved blood sugar control. In addition to its primary use in diabetes management, semaglutide has shown promising results in weight management as well.

Studies have demonstrated that patients taking semaglutide experienced significant weight loss compared to those on placebo, making it a valuable option for individuals struggling with obesity. Semaglutide is administered via subcutaneous injection once weekly and is well-tolerated by most patients, with common side effects including nausea and vomiting. Overall, semaglutide represents a significant advancement in the treatment of both diabetes and obesity, offering patients an effective and convenient therapeutic option.